“Recognizing the duty of the Federal Government to lead the world in biomedical research.”
No CRS summary available for this bill.
This section expresses the sense of the House of Representatives that the biomedical research and development capacity of the United States is a national asset that must be protected, improved, and expanded, that Federal efforts through the National Institutes of Health are essential to maintaining U.S. leadership in biomedical advancement, and that the Federal Government should double its investment in biomedical research over the next decade. The section further states that such investments should support basic research on the human body and external factors affecting it, translational science to accelerate access to novel treatments, high-risk high-reward projects, collaborative resources, and the integration of research findings into clinical practice, while targeting specific outcomes including reversing the recent decline in U.S. life expectancy, reducing cancer death rates, lowering the burden of Alzheimer’s disease and related dementias, eliminating deaths on transplant waiting lists, and developing interventions for chronic symptoms of infections such as COVID–19, Lyme disease, and Epstein-Barr virus.